Acme Universal IPO Subscription Status
SMEUpcomingChecked · GMP unchanged since
Acme Universal IPO Details
Acme Universal Financials ₹ in crore
Detailed financials for this issue aren’t available yet.
Acme Universal IPO Lot Size & Minimum Investment by investor category
| Application | Shares | Amount at ₹71 |
|---|---|---|
| Individual investor (min)minimum application | 3,200 | ₹2,27,200 |
The minimum application is 3,200 shares, ₹2,27,200 at the ₹71 cut-off. Since 1 July 2025 SME issues take a minimum application of ₹2,00,000 or more from individual investors; the HNI minimum is set in the RHP. Amounts are shown at the upper band because applications are made at the cut-off price.
Acme Universal IPO Strengths & Risks as disclosed in the DRHP
Strengths and risk factors from this issue’s prospectus aren’t available yet.
How to check Acme Universal IPO allotment status
Allotment is decided and published by the issue’s registrar, not by the exchange and not by alphave. For Acme Universal, the registrar is Maashitla Securities Pvt. Ltd. — allotment is finalised in the days between the issue closing on 30 Sept 2026 and listing on 06 Oct 2026.
Allotment and refund dates follow SEBI’s T+3 listing timeline in trading days and are tentative until the registrar and the exchange confirm them. alphave does not hold allotment results — only the registrar can show whether an application was allotted.
The registrar publishes allotment on its own portal: Maashitla. Your bank will also show the blocked amount released if shares were not allotted.
Acme Universal IPO Subscription Status FAQs
How do I check Acme Universal IPO subscription status?
NSE and BSE publish the category-wise bids for every open issue during bidding hours. This page reads that feed and shows the QIB, NII and retail book, plus one row per day so the build-up over the issue can be compared.
What does 2× subscription mean?
Subscription of 2× means bids were received for twice the number of shares offered in that category. When a category is oversubscribed, allotment in it is decided by the registrar under the basis-of-allotment rules — retail by lottery for the minimum lot, for example.
Acme Universal IPO Registrar where allotment and refund queries go
The registrar processes the allotment and the refunds. Contact details are as printed in the offer document; the exchange and your broker cannot change an allotment.
How to Apply for the Acme Universal IPO ASBA and UPI, as SEBI sets them
- Apply through your broker’s IPO window or your bank’s net banking (ASBA). The money stays in your own account and is only blocked until allotment.
- Choose the number of lots and bid at the cut-off price. SME issues take a minimum application of two lots, so the smallest valid bid is the amount shown in the lot table above.
- If you applied through a broker, approve the UPI mandate in your payment app. The mandate must be approved by 5 pm on the day after your bid, and by 5 pm on the closing day for bids made on the last day (30 Sept 2026).
- One application per PAN. A second application under the same PAN is rejected, and both may be.
- After allotment the blocked amount is released for shares not allotted. Allotment and refund queries go to the registrar, Maashitla Securities Pvt. Ltd., not to the exchange or the broker.
What is GMP in an IPO?
Grey Market Premium is the price at which an unlisted IPO application or share changes hands informally, before the stock is listed on the exchange. It is quoted as a rupee figure over the issue price: a premium of ₹0 on a ₹71 upper band means the grey market is dealing at ₹71.
The grey market is an over-the-counter market between private dealers. It is not operated or supervised by NSE, BSE or SEBI, no trade is settled through a clearing corporation, and no dealer is obliged to publish or honour a quote. Figures are collected by third-party reporters and different sources routinely disagree, which is why a premium can move sharply within a day or vanish entirely once bidding closes.
Grey Market Premium is an unofficial, unregulated over-the-counter datapoint reported by third parties. It is not a price, a forecast, or an indication of listing gains, and is not investment advice.